Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | lutetium Lu 177 dotatate |
| Synonyms | |
| Therapy Description |
Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog which may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| lutetium Lu 177 dotatate | Lutathera | LuTate|177Lu-Octreotate|177 Lu-DOTA-Tyr3-octreotate | Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog which may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02754297 | Phase II | lutetium Lu 177 dotatate | Personalized PRRT of Neuroendocrine Tumors (P-PRRT) | Recruiting | CAN | 0 |
| NCT03971461 | Phase II | lutetium Lu 177 dotatate | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | Recruiting | USA | 0 |
| NCT04106843 | Phase II | lutetium Lu 177 dotatate | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | Withdrawn | USA | 0 |
| NCT04529044 | Phase II | lutetium Lu 177 dotatate | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Not yet recruiting | USA | 0 |
| NCT04609592 | Phase I | lutetium Lu 177 dotatate | Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Not yet recruiting | USA | 0 |
| NCT04614766 | Phase Ib/II | 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) | Not yet recruiting | USA | 0 |
| NCT04082520 | Phase II | lutetium Lu 177 dotatate | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | Recruiting | USA | 0 |
CKB BOOST